Goodwin Biotechnology Inc. Completes cGMP Manufacturing of AREVA Med's Conjugate

* Reuters is not responsible for the content in this press release.

Mon Sep 14, 2009 8:03am EDT 

PLANTATION, Fla., Sept. 14, 2009 (GLOBE NEWSWIRE) -- Goodwin Biotechnology Inc.
(GBI) announced today the completion of the cGMP manufacturing and vialing of
AREVA Med's monoclonal antibody-chelator conjugate. As part of AREVA Med's
Lead-212 (212Pb) initiative, the conjugate will be used in Phase I clinical
trials to treat several types of deadly forms of cancers. AREVA Med will benefit
from the vast expertise in the nuclear industry from AREVA, its parent company,
that allowed for the production of this radioisotope previously considered a
scarce resource.

David Fischer, EVP of GBI, said, "We are very pleased to have completed the
manufacturing of AREVA Med's conjugate. After some promising pre-clinical data,
we look forward to seeing the outcome of the first in man studies."

About Goodwin Biotechnology Inc.

GBI is one of the earliest biologics contract manufacturing organizations
(CMOs), established in 1992. GBI specializes in process development and cGMP
compliant mammalian cell culture manufacturing of bio-therapeutics for
pre-clinical studies and clinical trials. GBI's clients include small to
midsized biotech companies throughout North America and Europe, as well as
universities, renowned cancer research institutes and various branches of the
U.S. government. GBI offers its clients the experience of an established U.S.
Contract Manufacturing Organization, and provides services in a fully integrated
offering, including process development, cell banking, cGMP manufacturing,
conjugation, vialing, and distribution to the clinical trial sites.
www.goodwinbio.com

The Goodwin Biotechnology Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=5202

About AREVA Med LLC.

AREVA Med LLC is a subsidiary of AREVA with manufacturing facilities in 43
countries and a sales network in more than 100 countries. AREVA offers customers
reliable technological solutions for CO2-free power generation and electricity
transmission and distribution. AREVA is the world leader in nuclear power and
the only company to cover all industrial activities in this field. Our 75,000
employees are committed to continuous improvement on a daily basis, making
sustainable development the focal point of the group's industrial strategy.
AREVA's businesses help meet the 21st century's greatest challenges: making
energy available to all, protecting the planet, and acting responsibly towards
future generations. www.areva.com

The AREVA Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=5221

-0-
CONTACT:  AREVA Med LLC
          Patrick Bourdet, President & CEO
          (301) 841-1600
          patrick.bourdet@areva.com
          4800 Hampden Lane, Suite 1100
          Bethesda, Maryland 20814

          Goodwin Biotechnology Inc.
          David Fischer, EVP
          (954) 327-9613
          dfischer@goodwinbio.com
          1850 NW 69 Avenue
          Plantation, Florida 33313
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.